Drug intelligence / Profile preview

rNV-2v

Development stage: Phase 1
Lead developer: Icon Genetics
Modality: Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

rNV-2v is a bivalent virus-like particle (VLP) vaccine candidate designed to prevent acute gastroenteritis caused by norovirus infection. It is composed of virus-like particles self-assembled from the major capsid proteins (VP1) of the norovirus GI.4 Chiba 407 (1987) and GII.4 Aomori 2 (2006) strains. The vaccine works by eliciting both humoral and cellular immune responses, including the production of total serum immunoglobulins, serum IgA, and CD4+ polypositive T cells, against these specific norovirus genotypes. It is manufactured by Icon Genetics GmbH using its magnICON® technology.

Other names: norovirus GI.4 / GII.4 bivalent VLP vaccineGI.4 Chiba 407 (1987) and GII.4 Aomori 2 (2006) VLP-based norovirus vaccine candidate

Targets

GII.17 VP1 (Norovirus GII.17 VP1)GII.4 VP1 (Norovirus GII.4 VP1)

Beyond the preview

Go deeper on rNV-2v.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rNV-2v.

Explore the full profile